Dan Arias

Is that more of a placement comment or a pull-through comment? Where do you think the opportunity is strongest there?

does that assume the full $150 million of cost savings is captured this year

Can you just dive into the acceleration a bit? What does the momentum there look like

can you maybe talk about cost management in the current environment

food retail was pretty strong here. Is something picking up? Or is that just sort of the inherent lumpiness of that business

how would you characterize the pharmacopeia opportunity over there that you talked about a little bit last quarter just in terms of what might be tangible

can you maybe just compare what you expect on the lab/biopharma side versus more of the industrial side

to what extent do you think onshoring demand can work itself into the picture for 2026 versus 2027 and beyond

that sounds like it's now functionally $0.40 lower. Does that include some offset activities? Or is that the gross impact

does visibility into demand look like it's changing at all or at least stabilizing in some way, such that a forecast one way or another has more confidence behind it

The capabilities in Mexico, I think that's through Biokix, if I remember right. It used to be Pipette tips and life sciences reagents

if you were to get some de-escalation here, like, it's possible do you see the chance for some stickiness that could kind of leave the door open for a benefit

is there any change in the way that you're feeling about industrial this year? I mean, to Patrick's point, it does seem like there's some good overall momentum in product inspection

I just want to understand the assumptions on biopharma, which looks like it's gradually recovering here

are you finding that some of the early uptick signals that you're talking about are they coming from the companies that have successfully raised money?

Can you just sort of refresh us on the timing of coming to market and then what your uptake trajectory might be?

on the GEL contributions, which I think you've kind of pointed to as being heavily weighted in in 4Q for $10 million or so, how should we model that sequentially in the quarters after that?

can you elaborate a little bit on the biotech element and just how much of the incremental enthusiasm that you might be pointing to is due to some of the larger biotech companies versus some of the...

Can you just sort of explicitly update us on the confidence that you have in that business not getting caught up there?

Can you just help us with what the ramp-up periods look like for volumes?

What kind of step down should we assume in the back half of the year? It seems like you're north of 20% for the first half

Do you see yourself as being potentially acquisitive and particularly on something larger than maybe a bolt-on over the next 12 months to 18 months?

on consumables, how are you thinking about the pull-through rate for LUNIPOR this year? Is that something that you think can grow as an average?

does that assume that both academic and biotech are growing at that point? Or is it what gets you there really just continued pharma strength

what kind of 80-20 type rule exists when it comes to these cell therapy accounts?

plus 1% organic this quarter, ex the GMP customers and you're expecting the same thing next quarter ex those accounts, 3% without them

the EBITDA threshold could be managed to, especially since I think that's the one that's actually closer to hitting the target

Can you expand on where the funding is coming from for the 2/3 of the academic customers that aren't tied to the NIH?

Is there a growth rate for the quarter? And just given what we're talking about, about some of the fluctuations in pharma ordering patterns

what kind of growth expectations do you have for that piece next quarter?

Is that 25% that you're talking about inclusive of some ASP increase?

to the extent that, that involves R&D, is there data next year that we should look out for?

on data, can you just maybe orient us on expectations for the back half year.

What's gone the way that you expected within your program? What's been a bit of a surprise?

Is there an implicit ASP assumption that you can share maybe not necessarily the exact dollar amount per se

you called out Chemical Analysis is doing well. That's been one of the areas that people have just had some concern broadly across the space.

I think that there might have been also some phasing in pharma services that was material. Is that a quantifiable amount?

I'm curious if you think there's anything that's sort of an offset there that maybe 90 days later, you're feeling a little bit better about

Is mid singles plus the right way to think about things

are you finding that that's actually translating the spending plans

I'm just curious whether demand from small and emerging biotech is getting any better from where you sit

what are you seeing on the research and industrial side? Is that fluid in a way that you think introduces some additional risk

just given the moving parts on the hardware side, it would be helpful to know how you see growth there in the back half

can you just maybe expand on the extent to which it feels like the spending decisions are being influenced by the macro factors at play

to what extent do you see [ pill ] count increases underpinning that such that you can think about an incrementally larger opportunity

Is there a margin impact that we should be mindful of there? I know in the early days, there can actually be some downward pressure

is there anything that you can say about mass spec in biopharma? And the reason I asked just because very clear that PFAS is helping LC-MS pretty significantly

to what extent do you still see there being additional capacity needs in the lab based on the water testing side, in the US

to what extent do you feel like the uptake there is partly a function of or being helped by the LC replacement cycle